ArticleBMC sports science, medicine & rehabilitation2026
Persian translation, cross-cultural adaptation, reliability, and validity of the updated Oslo sports trauma research centre questionnaire on health problems.
Article in BMC sports science, medicine & rehabilitation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe Oslo Sports Trauma Research Centre Questionnaire on Health Problems (OSTRC-H2) is a validated tool in its original English version for monitoring the full spectrum of health issues in athletes, but no Persian version exists. This study aimed to translate, culturally adapt, and evaluate the reliability and measurement properties, including internal consistency, test-retest reliability, and construct validity, of the Persian version of the updated OSTRC-H2 questionnaire for use with Persian-speaking elite athletes.
methodsThis methodological study employed a cross-sectional and longitudinal design. The OSTRC-H2 was translated into Persian following international guidelines. A total of 207 elite athletes from various sports completed the questionnaire at baseline and again after 72 h for test-retest reliability. To evaluate feasibility and describe the prevalence of health problems in this cohort, defined as any reported issue according to the OSTRC-H2 case definition, athletes also completed the questionnaire weekly for 12 weeks. Measurement properties evaluated included internal consistency (Cronbach’s alpha), test-retest reliability (intraclass correlation coefficient, ICC(2,1)), construct validity (Spearman correlations with pain, days lost, and training load), responsiveness (standardized response mean [SRM], effect size [ES]), and floor/ceiling effects.
resultsThe response rate was 98% (2435/2484 weekly questionnaires). The mean weekly prevalence of any health problems was 25.3% (95% CI: 23.6–27.0). Of the 628 health problems reported, acute injuries were most common (59.5%), followed by overuse injuries (28.3%) and illnesses (12.1%). Test-retest reliability was strong (ICC range: 0.82–1.00), and internal consistency was high (Cronbach’s alpha range: 0.81–1.00). The severity score showed strong positive correlations with pain intensity (rₛ range: 0.703–0.812) and days lost (rₛ range: 0.752–0.881), and moderate negative correlations with weekly training load. The questionnaire demonstrated large responsiveness to changes in health status (SRM range: 1.58–1.92; ES range: 1.83–2.21). No significant floor or ceiling effects were detected.
conclusionsThe Persian OSTRC-H2 is a feasible, reliable, valid, and responsive instrument for comprehensive health problem surveillance in Persian-speaking elite athletes. It is recommended for use in sports surveillance and monitoring programs to track the burden of injury and illness in this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.